Rubius Therapeutics Stock Current Valuation
| RUBYDelisted Stock | USD 0.08 0.02 17.00% |
Valuation analysis of Rubius Therapeutics helps investors to measure Rubius Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Rubius Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Rubius Therapeutics is based on 3 months time horizon. Increasing Rubius Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Rubius Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Rubius Pink Sheet. However, Rubius Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.083 | Real 0.0789 | Hype 0.08 | Naive 0.11 |
The intrinsic value of Rubius Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Rubius Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Rubius Therapeutics helps investors to forecast how Rubius pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Rubius Therapeutics more accurately as focusing exclusively on Rubius Therapeutics' fundamentals will not take into account other important factors: Rubius Therapeutics Company Current Valuation Analysis
Rubius Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Rubius Therapeutics Current Valuation | 22.18 M |
Most of Rubius Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rubius Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Rubius Therapeutics has a Current Valuation of 22.18 M. This is 99.85% lower than that of the Biotechnology sector and 99.52% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.87% higher than that of the company.
Rubius Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rubius Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Rubius Therapeutics could also be used in its relative valuation, which is a method of valuing Rubius Therapeutics by comparing valuation metrics of similar companies.Rubius Therapeutics is currently under evaluation in current valuation category among its peers.
Rubius Fundamentals
| Return On Equity | -1.85 | |||
| Return On Asset | -0.47 | |||
| Current Valuation | 22.18 M | |||
| Shares Outstanding | 90.4 M | |||
| Shares Owned By Insiders | 5.55 % | |||
| Shares Owned By Institutions | 72.61 % | |||
| Number Of Shares Shorted | 1.53 M | |||
| Price To Book | 0.42 X | |||
| EBITDA | (169.55 M) | |||
| Net Income | (179.67 M) | |||
| Cash And Equivalents | 140.71 M | |||
| Cash Per Share | 1.56 X | |||
| Total Debt | 76.15 M | |||
| Debt To Equity | 1.17 % | |||
| Current Ratio | 4.63 X | |||
| Book Value Per Share | 0.17 X | |||
| Cash Flow From Operations | (150.14 M) | |||
| Short Ratio | 0.49 X | |||
| Earnings Per Share | (2.27) X | |||
| Target Price | 1.0 | |||
| Number Of Employees | 20 | |||
| Beta | 2.45 | |||
| Market Capitalization | 7.5 M | |||
| Total Asset | 23.07 M | |||
| Z Score | -23.1 | |||
| Net Asset | 23.07 M |
About Rubius Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rubius Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rubius Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rubius Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Rubius Pink Sheet
If you are still planning to invest in Rubius Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rubius Therapeutics' history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |